Department of Orthopedics, University of Bologna, Istituto Rizzoli, Bologna, Italy.
Clin Orthop Relat Res. 2010 Nov;468(11):2860-6. doi: 10.1007/s11999-010-1476-4.
The choices of treatment for patients with extensive tumors of the femur include total femur megaprosthesis or large allograft-prosthetic composites. Previous reports suggest variable survival ranging from 60-70% at 1 to 2 years. However, these studies described earlier prostheses and techniques.
QUESTIONS/PURPOSES: To confirm previous reports we determined (1) risk of local recurrence; (2) overall survivorship; and (3) function in patients with total femur reconstructions for tumors.
We retrospectively reviewed 23 patients with total femur megaprostheses implanted between 1987 and 2006 after resection of bone tumors. Two patients lost at followup were excluded; the remaining 21 included 15 males and six females with a mean age of 21 years. The mean followup was 48 months (range, 1 month 17 years). Function was assessed according to the MSTS System II.
No patient developed a local recurrence during followup. At last followup, six patients were continuously disease-free at a mean of 148 months, one patient had no evidence of disease after treatment of a recurrence, one patient was alive with disease, and 13 patients died of their disease at a mean time of 17 months. In 15 patients evaluated with the MSTS score, the mean score was 66%; four patients had over 75%, eight from 51% to 75%, three from 26% to 50%. Four patients (19%) had complications requiring further surgery in absence of trauma. A fifth patient had a posttraumatic periprosthetic fracture.
A total femur prosthesis allows a limb-preserving procedure in tumors with extensive femoral involvement or in the presence of a skip lesion along the femur. The prognosis of these tumors is poor, but this reconstruction provides function with a relatively low rate of major complications.
对于股骨广泛肿瘤患者的治疗选择包括全股骨假体置换或大异体骨-假体复合材料。先前的报告表明,1 至 2 年的生存率为 60-70%。然而,这些研究描述了早期的假体和技术。
问题/目的:为了证实先前的报告,我们确定了(1)局部复发的风险;(2)总体生存率;(3)肿瘤患者全股骨重建的功能。
我们回顾性分析了 1987 年至 2006 年间因骨肿瘤切除后植入全股骨假体的 23 例患者。随访中丢失的两名患者被排除在外;其余 21 例包括 15 名男性和 6 名女性,平均年龄为 21 岁。平均随访时间为 48 个月(范围为 1 个月至 17 年)。根据 MSTS 系统 II 评估功能。
在随访期间,没有患者发生局部复发。最后一次随访时,6 例患者在平均 148 个月时持续无疾病,1 例患者在复发治疗后无疾病证据,1 例患者有疾病存活,13 例患者在平均 17 个月时死于疾病。在 15 例接受 MSTS 评分评估的患者中,平均评分为 66%;4 例患者得分超过 75%,8 例患者得分在 51%至 75%之间,3 例患者得分在 26%至 50%之间。4 名患者(19%)在没有外伤的情况下发生需要进一步手术的并发症。第五例患者发生了创伤性假体周围骨折。
全股骨假体允许在股骨广泛受累或股骨存在跳跃性病变的情况下进行保肢手术。这些肿瘤的预后较差,但这种重建提供了功能,且主要并发症的发生率相对较低。